Site-specific labeling methods and molecules produced thereby
View Patent ↗The present invention provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.
1. A modified antibody or antigen binding fragment thereof, wherein said wherein said antibody comprises an amino acid sequence selected from SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:63, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:139, SEQ ID NO:149, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:160, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:178, SEQ ID NO:248, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:259, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:277, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:356, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:380, SEQ ID NO:384, SEQ ID NO:386, SEQ ID NO:387, or SEQ ID NO:388.
2. An immunoconjugate comprising the modified antibody or antigen binding fragment thereof of claim 1 , and a terminal group, wherein said terminal group is attached to the modified antibody or antigen binding fragment by a linker having the structure according to Formula (I-b):
wherein:
a)
L 1 is -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is
L 2 is -A 2 -, wherein A 2 is —(CH 2 ) n C(═O;
L 3 is -A 3 -, wherein A 3 is
and
L 4 is
b) L is a -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is —(CH 2 ) n C(═O)NH—;
L 2 is a bond-; L 3 is -A 3 -, wherein A 3 is —(CH 2 ) n C(═O)—, and L 4 is a bond;
c) L 1 is a -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S—, X 2 is —CHR 4 (CH 2 ) n C(═O)NH— and R 4 is —C(═O)OH;
L 2 is a bond; L 3 is -A 3 -, wherein A 3 is —(CH 2 ) n C(═O)— and, L 4 is a bond;
d) L 1 is -A 1 X 2 —, where A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is —(CH 2 )C(═O)NH—;
L 2 is a bond; L 3 is a bond, and L 4 is -A 4 - wherein A 4 is —(CH 2 ) n NHC(═O)—;
e) L 1 is -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is —(CH 2 )C(═O)NH—;
L 2 is a bond; L 3 is a bond; L 4 is -A 4 -, wherein A 4 is —(CH 2 ) n C(═O)—;
f) L 1 is -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is —(CH 2 )C(═O)NH—;
L 2 is -A 2 -, wherein A 2 is —(CH 2 ) n C(═O;
L 3 is -A 3 -, wherein A 3 is
and
L 4 is
g) L 1 is a -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S— and X 2 is —(CH 2 )C(═O)NH—;
L 2 is a bond-; L 3 is -A 3 -, wherein A 3 is —(CH 2 ) n C(═O)—, and L 4 is a bond; or
h) L 1 is a -A 1 X 2 —, wherein A 1 is —C(═O)NH(CH 2 ) n S—, X 2 is —CHR 4 (CH 2 ) n C(═O)NH— and R 4 is —C(═O)OH;
L 2 is a bond; L 3 is -A 3 -, wherein A 3 is —(CH 2 ) n C(═O)—, and L 4 is a bond.
3. The immunoconjugate of claim 2 , wherein the terminal group is a moiety selected from an anti-inflammatory agent, an anticancer agent, an antifungal agent, an antibacterial agent, an anti-parasitic agent, an anti-viral agent and an anesthetic agent.
4. The immunoconjugate of claim 3 , wherein the terminal group is selected from a V-ATPase inhibitor, a HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizers, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, an inhibitors of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, an EG5 inhibitor, an HDAC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder, a proteasome inhibitor, and a DHFR inhibitor.
5. The immunoconjugate of claim 2 , wherein the terminal group is selected from a fluorophore, a chromophore, a quantum dot, a magnetic probe, a radioactive probe, an imaging reagent, or a contrast reagent.
6. A method of treating a Her2 positive cancer comprising administering to a human in need thereof an effective amount of the immunoconjugate of claim 2 or a pharmaceutical composition thereof.